A new male birth control pill passed tests of safety and tolerability when healthy men used it daily for a month, and it produced hormone responses consistent with effective contraception, according to researchers at two institutions testing the drug. The Phase 1 study results was presented Sunday, March 24 at ENDO 2019, the Endocrine Society’s annual meeting in New Orleans, La.
The experimental male oral contraceptive is called 11-beta-methyl-19-nortestosterone dodecylcarbonate, or 11-beta-MNTDC. It is a modified testosterone that has the combined actions of a male hormone (androgen) and a progesterone, said the study’s co-senior investigator, Christina Wang, M.D., Associate Director, Clinical and Translational Science Institute at Los Angeles Biomed Research Institute (LA BioMed), Torrance, Calif.
“Our results suggest that this pill, which combines two hormonal activities in one, will decrease sperm production while preserving libido,” Wang said. He added that the drug would take at least three 60 to 90 days to affect sperm production and that safe, reversible hormonal male contraception should be available in about 10 years.